Carole Faig
Direttore/Membro del Consiglio presso HENRY SCHEIN, INC.
Patrimonio netto: 198 463 $ in data 30/04/2024
Relazioni attive
Nome | Sesso | Età | Società collegate | Collaborazione |
---|---|---|---|---|
Ronald South | M | 62 | 16 anni | |
Michael Ettinger | M | 63 | 30 anni | |
Stanley Bergman | M | 74 | 44 anni | |
Carol Raphael | F | 81 | 12 anni | |
Kelly Murphy | F | 43 | 13 anni | |
Anne Margulies | F | 68 | 6 anni | |
Talha Ashraf | M | - |
QuVa Pharma, Inc.
QuVa Pharma, Inc. Pharmaceuticals: MajorHealth Technology QuVa Pharma, Inc. provides sterile compounding pharmacy services. It develops, manufactures and distributes compounded sterile preparations. The firm provides vital compounded medications for obstetrics, OR, anesthesia, general medicine, cardiovascular, ER, and pain management. The company was founded by Stuart Hinchen and Peter Linsay Jenkins in 2015 and is headquartered in Austin, TX. | 3 anni |
Caroline Stout | F | 33 |
Affinia Therapeutics, Inc.
Affinia Therapeutics, Inc. BiotechnologyHealth Technology Affinia Therapeutics, Inc. is a preclinical stage company, which engages in the research and development of gene therapy. It offers Affinia Rationally-designed Therapies (ART) platform, which develops novel therapies, focusing on the key components of a gene therapy: capsids, which are the outer shells of a virus used to package the genetic code to treat a disease; promoters, which control how the cells read the genetic code that is delivered; and manufacturing approaches, which determine the quality and cost of potential medicines. The company was founded by Luk Vandenberghe, Botond Roska, and Aaron Tward in 2019 and is headquartered in Waltham, MA. | 3 anni |
Philip Laskaway | M | 82 | 22 anni | |
Rick Modi | M | 55 |
Affinia Therapeutics, Inc.
Affinia Therapeutics, Inc. BiotechnologyHealth Technology Affinia Therapeutics, Inc. is a preclinical stage company, which engages in the research and development of gene therapy. It offers Affinia Rationally-designed Therapies (ART) platform, which develops novel therapies, focusing on the key components of a gene therapy: capsids, which are the outer shells of a virus used to package the genetic code to treat a disease; promoters, which control how the cells read the genetic code that is delivered; and manufacturing approaches, which determine the quality and cost of potential medicines. The company was founded by Luk Vandenberghe, Botond Roska, and Aaron Tward in 2019 and is headquartered in Waltham, MA. | 5 anni |
Scott Serota | M | 67 | 3 anni | |
Jennifer Ferrero | F | - | - | |
Mohamad Ali | M | 53 | 3 anni | |
Stuart Hinchen | M | - |
QuVa Pharma, Inc.
QuVa Pharma, Inc. Pharmaceuticals: MajorHealth Technology QuVa Pharma, Inc. provides sterile compounding pharmacy services. It develops, manufactures and distributes compounded sterile preparations. The firm provides vital compounded medications for obstetrics, OR, anesthesia, general medicine, cardiovascular, ER, and pain management. The company was founded by Stuart Hinchen and Peter Linsay Jenkins in 2015 and is headquartered in Austin, TX. | 9 anni |
Reed Tuckson | M | 73 | 3 anni | |
Peter Linsay Jenkins | M | - |
QuVa Pharma, Inc.
QuVa Pharma, Inc. Pharmaceuticals: MajorHealth Technology QuVa Pharma, Inc. provides sterile compounding pharmacy services. It develops, manufactures and distributes compounded sterile preparations. The firm provides vital compounded medications for obstetrics, OR, anesthesia, general medicine, cardiovascular, ER, and pain management. The company was founded by Stuart Hinchen and Peter Linsay Jenkins in 2015 and is headquartered in Austin, TX. | 9 anni |
Dave Grayzel | M | 56 |
Affinia Therapeutics, Inc.
Affinia Therapeutics, Inc. BiotechnologyHealth Technology Affinia Therapeutics, Inc. is a preclinical stage company, which engages in the research and development of gene therapy. It offers Affinia Rationally-designed Therapies (ART) platform, which develops novel therapies, focusing on the key components of a gene therapy: capsids, which are the outer shells of a virus used to package the genetic code to treat a disease; promoters, which control how the cells read the genetic code that is delivered; and manufacturing approaches, which determine the quality and cost of potential medicines. The company was founded by Luk Vandenberghe, Botond Roska, and Aaron Tward in 2019 and is headquartered in Waltham, MA. | 4 anni |
Joseph Herring | M | 68 | 8 anni | |
Deborah Derby | F | 60 | 3 anni | |
Bradley Sheares | M | 67 | 14 anni | |
Charles Sigal | M | 72 |
Affinia Therapeutics, Inc.
Affinia Therapeutics, Inc. BiotechnologyHealth Technology Affinia Therapeutics, Inc. is a preclinical stage company, which engages in the research and development of gene therapy. It offers Affinia Rationally-designed Therapies (ART) platform, which develops novel therapies, focusing on the key components of a gene therapy: capsids, which are the outer shells of a virus used to package the genetic code to treat a disease; promoters, which control how the cells read the genetic code that is delivered; and manufacturing approaches, which determine the quality and cost of potential medicines. The company was founded by Luk Vandenberghe, Botond Roska, and Aaron Tward in 2019 and is headquartered in Waltham, MA. | 4 anni |
Kurt Kuehn | M | 69 | 8 anni | |
Walter Siegel | M | 65 | 11 anni | |
Luk Vandenberghe | M | 47 |
Affinia Therapeutics, Inc.
Affinia Therapeutics, Inc. BiotechnologyHealth Technology Affinia Therapeutics, Inc. is a preclinical stage company, which engages in the research and development of gene therapy. It offers Affinia Rationally-designed Therapies (ART) platform, which develops novel therapies, focusing on the key components of a gene therapy: capsids, which are the outer shells of a virus used to package the genetic code to treat a disease; promoters, which control how the cells read the genetic code that is delivered; and manufacturing approaches, which determine the quality and cost of potential medicines. The company was founded by Luk Vandenberghe, Botond Roska, and Aaron Tward in 2019 and is headquartered in Waltham, MA. | 5 anni |
Mark Mlotek | M | 68 | 30 anni | |
Michael Racioppi | M | 69 | 32 anni | |
Ed Mathers Mathers | M | 64 |
Affinia Therapeutics, Inc.
Affinia Therapeutics, Inc. BiotechnologyHealth Technology Affinia Therapeutics, Inc. is a preclinical stage company, which engages in the research and development of gene therapy. It offers Affinia Rationally-designed Therapies (ART) platform, which develops novel therapies, focusing on the key components of a gene therapy: capsids, which are the outer shells of a virus used to package the genetic code to treat a disease; promoters, which control how the cells read the genetic code that is delivered; and manufacturing approaches, which determine the quality and cost of potential medicines. The company was founded by Luk Vandenberghe, Botond Roska, and Aaron Tward in 2019 and is headquartered in Waltham, MA. | 4 anni |
Sean Nolan | M | 56 |
Affinia Therapeutics, Inc.
Affinia Therapeutics, Inc. BiotechnologyHealth Technology Affinia Therapeutics, Inc. is a preclinical stage company, which engages in the research and development of gene therapy. It offers Affinia Rationally-designed Therapies (ART) platform, which develops novel therapies, focusing on the key components of a gene therapy: capsids, which are the outer shells of a virus used to package the genetic code to treat a disease; promoters, which control how the cells read the genetic code that is delivered; and manufacturing approaches, which determine the quality and cost of potential medicines. The company was founded by Luk Vandenberghe, Botond Roska, and Aaron Tward in 2019 and is headquartered in Waltham, MA. | 5 anni |
Trinh Clark | F | - | - | |
Mark Hillebrandt | M | - | 6 anni | |
Rob Aboud | M | 59 |
Affinia Therapeutics, Inc.
Affinia Therapeutics, Inc. BiotechnologyHealth Technology Affinia Therapeutics, Inc. is a preclinical stage company, which engages in the research and development of gene therapy. It offers Affinia Rationally-designed Therapies (ART) platform, which develops novel therapies, focusing on the key components of a gene therapy: capsids, which are the outer shells of a virus used to package the genetic code to treat a disease; promoters, which control how the cells read the genetic code that is delivered; and manufacturing approaches, which determine the quality and cost of potential medicines. The company was founded by Luk Vandenberghe, Botond Roska, and Aaron Tward in 2019 and is headquartered in Waltham, MA. | 5 anni |
Laura Richman | M | 60 |
Affinia Therapeutics, Inc.
Affinia Therapeutics, Inc. BiotechnologyHealth Technology Affinia Therapeutics, Inc. is a preclinical stage company, which engages in the research and development of gene therapy. It offers Affinia Rationally-designed Therapies (ART) platform, which develops novel therapies, focusing on the key components of a gene therapy: capsids, which are the outer shells of a virus used to package the genetic code to treat a disease; promoters, which control how the cells read the genetic code that is delivered; and manufacturing approaches, which determine the quality and cost of potential medicines. The company was founded by Luk Vandenberghe, Botond Roska, and Aaron Tward in 2019 and is headquartered in Waltham, MA. | 4 anni |
Leigh Benowitz | F | - | - | |
Aaron Tward | M | - |
Affinia Therapeutics, Inc.
Affinia Therapeutics, Inc. BiotechnologyHealth Technology Affinia Therapeutics, Inc. is a preclinical stage company, which engages in the research and development of gene therapy. It offers Affinia Rationally-designed Therapies (ART) platform, which develops novel therapies, focusing on the key components of a gene therapy: capsids, which are the outer shells of a virus used to package the genetic code to treat a disease; promoters, which control how the cells read the genetic code that is delivered; and manufacturing approaches, which determine the quality and cost of potential medicines. The company was founded by Luk Vandenberghe, Botond Roska, and Aaron Tward in 2019 and is headquartered in Waltham, MA. | 5 anni |
Olga Timoshkina | F | - | 3 anni | |
Michael Amodio | M | - | - | |
Andy Hudak | M | - | 3 anni | |
Nitin Duggal | M | - | 3 anni | |
Bradford Connett | M | - | 3 anni | |
Robert May | M | 56 |
Affinia Therapeutics, Inc.
Affinia Therapeutics, Inc. BiotechnologyHealth Technology Affinia Therapeutics, Inc. is a preclinical stage company, which engages in the research and development of gene therapy. It offers Affinia Rationally-designed Therapies (ART) platform, which develops novel therapies, focusing on the key components of a gene therapy: capsids, which are the outer shells of a virus used to package the genetic code to treat a disease; promoters, which control how the cells read the genetic code that is delivered; and manufacturing approaches, which determine the quality and cost of potential medicines. The company was founded by Luk Vandenberghe, Botond Roska, and Aaron Tward in 2019 and is headquartered in Waltham, MA. | 4 anni |
Petra Kaufmann | M | 58 |
Affinia Therapeutics, Inc.
Affinia Therapeutics, Inc. BiotechnologyHealth Technology Affinia Therapeutics, Inc. is a preclinical stage company, which engages in the research and development of gene therapy. It offers Affinia Rationally-designed Therapies (ART) platform, which develops novel therapies, focusing on the key components of a gene therapy: capsids, which are the outer shells of a virus used to package the genetic code to treat a disease; promoters, which control how the cells read the genetic code that is delivered; and manufacturing approaches, which determine the quality and cost of potential medicines. The company was founded by Luk Vandenberghe, Botond Roska, and Aaron Tward in 2019 and is headquartered in Waltham, MA. | 3 anni |
Reid Arstark | M | - | 3 anni | |
Scott Aladeen | M | - |
QuVa Pharma, Inc.
QuVa Pharma, Inc. Pharmaceuticals: MajorHealth Technology QuVa Pharma, Inc. provides sterile compounding pharmacy services. It develops, manufactures and distributes compounded sterile preparations. The firm provides vital compounded medications for obstetrics, OR, anesthesia, general medicine, cardiovascular, ER, and pain management. The company was founded by Stuart Hinchen and Peter Linsay Jenkins in 2015 and is headquartered in Austin, TX. | 3 anni |
Randall Pollard | M | 52 | 2 anni | |
Allison F. Blackwell | F | 59 | 2 anni | |
Lorelei McGlynn | F | 60 | 25 anni | |
Gerard K. Meuchner | M | - | 12 anni | |
Andrew T. Kaplan | M | 39 |
QuVa Pharma, Inc.
QuVa Pharma, Inc. Pharmaceuticals: MajorHealth Technology QuVa Pharma, Inc. provides sterile compounding pharmacy services. It develops, manufactures and distributes compounded sterile preparations. The firm provides vital compounded medications for obstetrics, OR, anesthesia, general medicine, cardiovascular, ER, and pain management. The company was founded by Stuart Hinchen and Peter Linsay Jenkins in 2015 and is headquartered in Austin, TX. | 9 anni |
Botond Roska | M | 54 |
Affinia Therapeutics, Inc.
Affinia Therapeutics, Inc. BiotechnologyHealth Technology Affinia Therapeutics, Inc. is a preclinical stage company, which engages in the research and development of gene therapy. It offers Affinia Rationally-designed Therapies (ART) platform, which develops novel therapies, focusing on the key components of a gene therapy: capsids, which are the outer shells of a virus used to package the genetic code to treat a disease; promoters, which control how the cells read the genetic code that is delivered; and manufacturing approaches, which determine the quality and cost of potential medicines. The company was founded by Luk Vandenberghe, Botond Roska, and Aaron Tward in 2019 and is headquartered in Waltham, MA. | 5 anni |
Stefanie Fleige | F | - | - | |
Steven W. Kess | M | - | 33 anni | |
Paula Cobb | F | 51 |
Affinia Therapeutics, Inc.
Affinia Therapeutics, Inc. BiotechnologyHealth Technology Affinia Therapeutics, Inc. is a preclinical stage company, which engages in the research and development of gene therapy. It offers Affinia Rationally-designed Therapies (ART) platform, which develops novel therapies, focusing on the key components of a gene therapy: capsids, which are the outer shells of a virus used to package the genetic code to treat a disease; promoters, which control how the cells read the genetic code that is delivered; and manufacturing approaches, which determine the quality and cost of potential medicines. The company was founded by Luk Vandenberghe, Botond Roska, and Aaron Tward in 2019 and is headquartered in Waltham, MA. | 4 anni |
Ann Marie Gothard | F | - | 8 anni | |
Charles Albright | M | 66 |
Affinia Therapeutics, Inc.
Affinia Therapeutics, Inc. BiotechnologyHealth Technology Affinia Therapeutics, Inc. is a preclinical stage company, which engages in the research and development of gene therapy. It offers Affinia Rationally-designed Therapies (ART) platform, which develops novel therapies, focusing on the key components of a gene therapy: capsids, which are the outer shells of a virus used to package the genetic code to treat a disease; promoters, which control how the cells read the genetic code that is delivered; and manufacturing approaches, which determine the quality and cost of potential medicines. The company was founded by Luk Vandenberghe, Botond Roska, and Aaron Tward in 2019 and is headquartered in Waltham, MA. | 3 anni |
Christopher Pendergast | M | 61 | 6 anni | |
Randall McLemore | M | - | - | |
Graham Barry Stanley | M | 56 | 20 anni | |
Diana Brainard | M | 53 |
Affinia Therapeutics, Inc.
Affinia Therapeutics, Inc. BiotechnologyHealth Technology Affinia Therapeutics, Inc. is a preclinical stage company, which engages in the research and development of gene therapy. It offers Affinia Rationally-designed Therapies (ART) platform, which develops novel therapies, focusing on the key components of a gene therapy: capsids, which are the outer shells of a virus used to package the genetic code to treat a disease; promoters, which control how the cells read the genetic code that is delivered; and manufacturing approaches, which determine the quality and cost of potential medicines. The company was founded by Luk Vandenberghe, Botond Roska, and Aaron Tward in 2019 and is headquartered in Waltham, MA. | 2 anni |
David Tsay | M | - | 2 anni |
Grafico relazionale
Relazione in diverse aziende
Relazioni precedenti
Nome | Sesso | Età | Società collegate | Collaborazione |
---|---|---|---|---|
Steven Paladino | M | 66 | 37 anni | |
Ayub Khattak | M | 39 | 14 anni | |
James Breslawski | M | 70 | 44 anni | |
Rishi Reddy | M | - | - | |
Joshua Ghaim | M | 56 | 2 anni | |
Erica Palsis | F | 38 | 2 anni | |
Sachin Jain | M | 43 | 2 anni | |
Chris Achar | M | 39 | 6 anni | |
Scott Stanford | M | 54 | 5 anni | |
Joanne Bradford | F | 60 | 3 anni | |
Maria Martinez | F | 66 | 3 anni | |
Aasim Javed | M | 40 | 3 anni | |
Xiang Ming Cui | M | 55 | 2 anni | |
John Gallagher | M | 51 | 2 anni | |
Thomas Leggett | M | 47 |
Affinia Therapeutics, Inc.
Affinia Therapeutics, Inc. BiotechnologyHealth Technology Affinia Therapeutics, Inc. is a preclinical stage company, which engages in the research and development of gene therapy. It offers Affinia Rationally-designed Therapies (ART) platform, which develops novel therapies, focusing on the key components of a gene therapy: capsids, which are the outer shells of a virus used to package the genetic code to treat a disease; promoters, which control how the cells read the genetic code that is delivered; and manufacturing approaches, which determine the quality and cost of potential medicines. The company was founded by Luk Vandenberghe, Botond Roska, and Aaron Tward in 2019 and is headquartered in Waltham, MA. | 3 anni |
Glenn Wada | M | - | - | |
Asish Xavier | M | - | 1 anni | |
David Arida | M | - | 2 anni | |
Ming Hui Gao | M | 51 | 3 anni | |
Suzanne Stone | F | - | 1 anni |
Statistiche
Paese | Relazioni | % del totale |
---|---|---|
Stati Uniti | 79 | 100.00% |
Età delle relazioni
Attive
Scorse
Uomo
Donna
Amministratori
Dirigenti
Provenienza delle relazioni
- Borsa valori
- Insiders
- Carole Faig
- Contatti personali